Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Ohio

Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Ohio

46 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi di Ohio.

Kota di Ohio

Teks studi resmi (Bahasa Inggris)

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Aultman Health Foundation, Canton
Ohio State University Comprehensive Cancer Center, Columbus

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06992427

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site#0154, Canton
Site#0117, Cincinnati
Site #0151, Cleveland
dan 1 lainnya

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06788990

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #10, Cleveland

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Miami Valley Hospital South, Centerville
Miami Valley Hospital, Dayton
Miami Valley Hospital North, Dayton
dan 3 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 10, Columbus

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07085091

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 06, Maumee

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07814248

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Miami Valley Hospital South, Centerville
Premier Blood and Cancer Center, Dayton
Miami Valley Hospital North, Dayton
dan 2 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

University of Cincinnati, Cincinnati
Ohio State University, Columbus

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07276399

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

University of Cincinnati, Cincinnati

Menerima pesertaFase 3

Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04892173

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
University of Cincinnati Cancer Center-West Chester, West Chester

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06980038

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Cleveland Clinic, Cleveland

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06385080

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Miami Valley Hospital South, Centerville
Cleveland Clinic Foundation, Cleveland
Premier Blood and Cancer Center, Dayton
dan 3 lainnya

Menerima pesertaFase 2

Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT04671667

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

UH Cleveland Medical Center, Cleveland

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

UH Seidman Cancer Center at UH Avon Health Center, Avon
Indu and Raj Soin Medical Center, Beavercreek
Saint Elizabeth Boardman Hospital, Boardman
dan 22 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site, Columbus

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06535607

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Ohio State University, Columbus

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06657222

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

University of Cincinnati, Cincinnati
Cleveland Clinic, Cleveland
Ohio State University, Columbus

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06163534

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ohio State University, Columbus

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity Investigational Site, Maumee

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Cleveland Clinic Foundation, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04333537

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Summa Health System - Akron Campus, Akron
Aultman Health Foundation, Canton
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
dan 2 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
ProMedica Flower Hospital, Sylvania
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
dan 1 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The Ohio State University, Columbus

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT05985655

SMP-3124LP in Adults With Advanced Solid Tumors

Ohio State University, Columbus

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06526819

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06627270

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Ohio State University, Columbus
Taylor Cancer Research Center, Maumee

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT03526835

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Ohio State University Comprehensive Cancer Center, Columbus

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT04754321

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05208762

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

UH Cleveland Medical Center, Cleveland
Stefanie Spielman Comprehensive Breast Center, Columbus

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

University of Cincinnati Medical Center, Cincinnati

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT07213934

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

GSK Investigational Site, Canton

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06256588

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

University of Cincinnati Medical Center, Cincinnati

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT07497607

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

The Cleveland Clinic Foundation, Cleveland

Menerima pesertaFase 2/3

Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT05893888

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06064877

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Apr 2026 · NCT05785741

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center, Columbus

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT06323460

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Cleveland Clinic, Cleveland
Taylor Cancer Research Center, Maumee

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

Ohio State University Medical Center, Columbus

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT01473784

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.